Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXS NASDAQ:MITO NASDAQ:PDSB OTCMKTS:RGRX NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.03$0.06$0.03▼$0.80$1.42M1.224,032 shs1,200 shsMITOStealth BioTherapeutics$0.32$0.32$0.16▼$1.03$23.54M1.46946,105 shsN/APDSBPDS Biotechnology$0.98+5.7%$1.12$0.85▼$3.48$43.56M1.11473,238 shs552,785 shsRGRXRegeneRx Biopharmaceuticals$0.16$0.09$0.00▼$0.16N/A152.26286 shsN/ASVRASavara$4.11+13.9%$3.42$1.89▼$4.30$623.94M0.461.15 million shs2.61 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%-34.71%0.00%+23.33%MITOStealth BioTherapeutics0.00%0.00%0.00%0.00%0.00%PDSBPDS Biotechnology+5.66%+2.40%-6.79%-14.90%-69.89%RGRXRegeneRx Biopharmaceuticals0.00%0.00%0.00%+80,400.00%+11,400.00%SVRASavara+13.85%+20.53%+16.43%+70.54%+9.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.03$0.06$0.03▼$0.80$1.42M1.224,032 shs1,200 shsMITOStealth BioTherapeutics$0.32$0.32$0.16▼$1.03$23.54M1.46946,105 shsN/APDSBPDS Biotechnology$0.98+5.7%$1.12$0.85▼$3.48$43.56M1.11473,238 shs552,785 shsRGRXRegeneRx Biopharmaceuticals$0.16$0.09$0.00▼$0.16N/A152.26286 shsN/ASVRASavara$4.11+13.9%$3.42$1.89▼$4.30$623.94M0.461.15 million shs2.61 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%0.00%-34.71%0.00%+23.33%MITOStealth BioTherapeutics0.00%0.00%0.00%0.00%0.00%PDSBPDS Biotechnology+5.66%+2.40%-6.79%-14.90%-69.89%RGRXRegeneRx Biopharmaceuticals0.00%0.00%0.00%+80,400.00%+11,400.00%SVRASavara+13.85%+20.53%+16.43%+70.54%+9.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AMITOStealth BioTherapeutics 0.00N/AN/AN/APDSBPDS Biotechnology 2.33Hold$10.00921.76% UpsideRGRXRegeneRx Biopharmaceuticals 0.00N/AN/AN/ASVRASavara 2.75Moderate Buy$7.5082.48% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, RGRX, PDSB, MITO, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025SVRASavaraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.0010/14/2025SVRASavaraLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/8/2025PDSBPDS BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PDSBPDS BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.009/3/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.008/15/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$5.00 ➝ $6.008/15/2025SVRASavaraHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$2.00 ➝ $5.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M0.44N/AN/A($2.06) per share-0.02MITOStealth BioTherapeutics$21.09M1.12N/AN/A($0.79) per share-0.41PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ARGRXRegeneRx Biopharmaceuticals$80KN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/AMITOStealth BioTherapeutics-$52.53M-$0.52N/AN/AN/AN/AN/A-142.81%N/APDSBPDS Biotechnology-$37.61M-$0.92N/AN/AN/AN/A-184.56%-79.00%11/13/2025 (Estimated)RGRXRegeneRx Biopharmaceuticals-$1.73MN/A0.00∞N/AN/AN/AN/AN/ASVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest SVRA, RGRX, PDSB, MITO, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025PDSBPDS Biotechnology-$0.21N/AN/AN/AN/AN/A11/11/2025Q3 2025SVRASavara-$0.13N/AN/AN/AN/AN/A8/13/2025Q2 2025PDSBPDS Biotechnology-$0.24-$0.21+$0.03-$0.21N/AN/A8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AMITOStealth BioTherapeuticsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ARGRXRegeneRx BiopharmaceuticalsN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AMITOStealth BioTherapeuticsN/A3.683.68PDSBPDS Biotechnology0.812.922.92RGRXRegeneRx BiopharmaceuticalsN/AN/AN/ASVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%MITOStealth BioTherapeutics2.21%PDSBPDS Biotechnology26.84%RGRXRegeneRx BiopharmaceuticalsN/ASVRASavara87.93%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%MITOStealth BioTherapeuticsN/APDSBPDS Biotechnology9.20%RGRXRegeneRx Biopharmaceuticals12.60%SVRASavara5.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableMITOStealth BioTherapeutics2973.55 millionN/ANot OptionablePDSBPDS Biotechnology2047.03 million42.70 millionOptionableRGRXRegeneRx Biopharmaceuticals3N/AN/ANot OptionableSVRASavara20172.84 million163.97 millionOptionableSVRA, RGRX, PDSB, MITO, and ADXS HeadlinesRecent News About These CompaniesSavara (NASDAQ:SVRA) Trading Up 10.4% - Time to Buy?October 20 at 6:40 PM | marketbeat.comLevi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 – SVRAOctober 20 at 4:20 PM | globenewswire.comDeadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitOctober 20 at 1:03 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRAOctober 20 at 12:01 PM | globenewswire.comClass Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact The Gross Law FirmOctober 20 at 8:45 AM | prnewswire.comSavara (NASDAQ:SVRA) Earns Overweight Rating from Analysts at Wells Fargo & CompanyOctober 20 at 8:27 AM | marketbeat.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 20 at 3:59 AM | prnewswire.comSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 20 at 3:39 AM | prnewswire.comSAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th DeadlineOctober 18 at 11:39 AM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRAOctober 18 at 10:00 AM | prnewswire.comLifesci Capital Estimates Savara's Q3 Earnings (NASDAQ:SVRA)October 18 at 2:39 AM | americanbankingnews.comSVRA Lead Plaintiff Deadline (11/7/25) Reminder: Savara Inc. Investors Should Contact Robbins LLP for Information About the Class Action LawsuitOctober 17, 2025 | globenewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud LawsuitOctober 17, 2025 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2025 in Savara Inc. Lawsuit – SVRAOctober 17, 2025 | globenewswire.comSavara promotes Wasfi to Chief Medical OfficerOctober 17, 2025 | msn.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRAOctober 17, 2025 | globenewswire.comLevi & Korsinsky Reminds Savara Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRAOctober 17, 2025 | prnewswire.comSavara Announces Chief Medical Officer (CMO) TransitionOctober 17, 2025 | businesswire.comSavara (NASDAQ:SVRA) Upgraded at Lifesci CapitalOctober 17, 2025 | americanbankingnews.comSavara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRAOctober 16, 2025 | globenewswire.comFaruqi & Faruqi Reminds Savara Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2025 - SVRAOctober 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVRA, RGRX, PDSB, MITO, and ADXS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.03 0.00 (0.00%) As of 10/17/2025 10:38 AM EasternAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Stealth BioTherapeutics NASDAQ:MITOStealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.PDS Biotechnology NASDAQ:PDSB$0.98 +0.05 (+5.66%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$0.97 -0.01 (-0.79%) As of 10/20/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.RegeneRx Biopharmaceuticals OTCMKTS:RGRX$0.16 0.00 (0.00%) As of 10/17/2025RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.Savara NASDAQ:SVRA$4.11 +0.50 (+13.85%) Closing price 10/20/2025 04:00 PM EasternExtended Trading$4.10 -0.02 (-0.36%) As of 10/20/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner JPMorgan Crushes Q3; But Is the Steady Eddy Stock Hitting A Wall? Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
